{"page":{"totalFilteredElements":330},"studies":[{"active":true,"description":"Prospektive, randomisierte, offene, multizentrische Phase III Studie zur Untersuchung der Wirksamkeit einer Therapie in Patienten mit metastasiertem kolorektalen Karzinom, nach erfolgter Resektion oder Ablation
DRKS00027138
","eudractNumber":"2020-006144-18","id":7450,"indications":[{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu1","name":"Karzinome des Dünn- und Dickdarms (Kolon, Rektum, Anus)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2021-11-17T12:40:54+01:00","shortTitle":"AIO-KRK-0418 / FIRE-9 - PORT","therapeutical":true,"therapyLines":[{"id":"tl_6","name":"Adjuvant"},{"id":"tl_9","name":"Metastatic"}]},{"active":true,"description":"Prospektive, randomisierte, offene, multizentrische Phase II Studie zur Untersuchung der Wirksamkeit von Tifluridin/Tipiracil plus Panitumumab im Vergleich zu Tifluridin/ Tipiracil plus Bevacizumab bei der Erstlinientherapie des metastasierten kolorektalen Karzinoms","eudractNumber":"2019-004223-20","id":7571,"indications":[{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu1","name":"Karzinome des Dünn- und Dickdarms (Kolon, Rektum, Anus)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[{"name":"ras-Gen","id":"mt_28"}],"nctNumber":"NCT05007132","phase":{"id":"ph_7","name":"Phase II"},"recruitmentStart":"2021-12-09T11:15:44+01:00","shortTitle":"AIO-KRK/YMO-0519 (Fire-8)","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"},{"id":"tl_9","name":"Metastatic"}]},{"active":true,"description":"A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study \nEvaluating The Safety And Efficacy Of Efruxifermin (EFX) In Subjects with Non-Cirrhotic Non-alcoholic Steatohepatitis (NASH) \nAnd Fibrosis","eudractNumber":"2023-505141-48-00","id":9598,"indications":[{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu2","name":"Leber (Hepatozelluläres Karzinom, HCC) / Gallenblase-/wege (Cholangiozelluläres Karzinom, CCC)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT06215716","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2024-03-28T10:10:05+01:00","shortTitle":"AK-US-001-0105","therapeutical":false,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"
A Phase 3, Open-label, Multicenter, Randomized Study of Xaluritamig Plus Abiraterone Versus Investigator’s Choice in Participants with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
","eudractNumber":"2025-520555-89","id":11331,"indications":[{"id":"pro","name":"Prostatakrebs"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT07213674","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2026-01-15T10:26:05+01:00","shortTitle":"AMG 509 20230239","therapeutical":true,"therapyLines":[{"id":"tl_2","name":"Zweitlinie"}]},{"active":true,"description":"A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-Tumor Activity of Subcutaneous Tarlatamab in Subjects with Extensive Stage Small Cell Lung Cancer (DeLLphi-308)","eudractNumber":"2024-511838-12-00","id":9817,"indications":[{"id":"lun","name":"Lungentumoren"},{"id":"lun1","name":"Kleinzelliges Bronchialkarzinom (SCLC)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT06598306","phase":{"id":"ph_14","name":"Phase I/IB"},"recruitmentStart":"2024-11-26T08:36:39+01:00","shortTitle":"AMG 757 20230298 (DeLLphi-308)","therapeutical":true,"therapyLines":[{"id":"tl_2","name":"Zweitlinie"}]},{"active":true,"description":"A Phase 1b Study Evaluating the Safety, Tolerability,\nPharmacokinetics, and Efficacy of Tarlatamab in Combination\nwith ZL-1310 with or without Anti-PD-L1 in Participants with\nSmall Cell Lung Cancer","eudractNumber":"2025-522888-15-00","id":11558,"indications":[{"id":"lun","name":"Lungentumoren"},{"id":"lun1","name":"Kleinzelliges Bronchialkarzinom (SCLC)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[{"name":"PD-1 (Programmed cell death protein 1)","id":"mt_43"},{"name":"PD-L1","id":"mt_25"}],"nctNumber":null,"phase":{"id":"ph_6","name":"Phase IB"},"recruitmentStart":"2026-05-28T14:19:18+02:00","shortTitle":"AMG 757 20250114 (DeLLphi 313)","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"},{"id":"tl_2","name":"Zweitlinie"}]},{"active":true,"description":"Randomized, placebo controlled Phase III Study of Induction and Consolidation chemotherapy with Venetoclax in adult patients with newly diagnosed acute myeloid Leukemia or Myelodyspalstic syndrome with ecxess Blasts-2","eudractNumber":"2023-507518-28-00","id":11260,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"},{"id":"leu","name":"Leukämien"},{"id":"leu2","name":"Akute myeloische Leukämie (AML)"}],"mutations":[],"nctNumber":"NCT04628026","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2025-08-05T13:17:41+02:00","shortTitle":"AMLSG 31-19","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"
Registerstudie zum biologischen Erkrankungsprofil und klinischen Verlauf bei der akuten myeloischen Leukämie und verwandten Vorläufer-Neoplasien und der akuten Leukämie unklarer Linienzugehörigkeit: Das AMLSG Biology and Outcome (BIO)-Projekt
","eudractNumber":null,"id":953,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"},{"id":"leu","name":"Leukämien"},{"id":"leu2","name":"Akute myeloische Leukämie (AML)"}],"mutations":[],"nctNumber":"NCT01252485","phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2013-08-01T13:27:10+02:00","shortTitle":"AMLSG BIO","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Zanubrutinib (Brukinsa®) in Patients With Waldenström's Macroglobulinemia (WM), Chronic Lymphocytic Leukemia (CLL) and Marginal Zone Lymphoma (MZL) - a Prospective Multicenter Observational Cohort Study","eudractNumber":null,"id":10642,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT05326308","phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2021-12-09T15:40:31+01:00","shortTitle":"ARIADNE","therapeutical":false,"therapyLines":[{"id":"tl_3","name":"Drittlinie"}]},{"active":true,"description":"

A Phase III, Randomized, Double-blind, Multicenter, Global
Study of Rilvegostomig or Pembrolizumab in Combination with
Platinum-based Chemotherapy for the First-line Treatment of
Patients with Metastatic Squamous Non-small Cell Lung Cancer
Whose Tumors Express PD-L1 (ARTEMIDE-Lung02; D702BC00001)

","eudractNumber":"2024-514281-39-00","id":11261,"indications":[{"id":"lun","name":"Lungentumoren"},{"id":"lun2","name":"Nicht-kleinzelliges Bronchialkarzinom (NSCLC)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[{"name":"PD-1 (Programmed cell death protein 1)","id":"mt_43"},{"name":"PD-L1","id":"mt_25"}],"nctNumber":"NCT06692738","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2025-05-15T12:46:50+02:00","shortTitle":"ARTEMIDE-Lung02","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]}]}